PALATINE, IL -- (Marketwired) -- 03/08/16 --
Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 28th Annual ROTH Capital Conference on Monday, March 14, 2016 at 11:30 a.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
The presentation will be webcast live and may be accessed by visiting Acura's website at www.acurapharm.com. A replay of the webcast will be available for 90 days.
About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.
In June 2011, the U.S. Food and Drug Administration approved OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION technology. In October 2015, Egalet Corporation, pursuant to a worldwide exclusive license, launched into the U.S. market OXAYDO (oxycodone HCL immediate-release tablets, CII), our Food and Drug Administration approved product incorporating our AVERSION technology. Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.
for Acura Investor Relations
Renmark Financial Communications Inc.
(416) 644-2020 or (514) 939-3989
Source: Acura Pharmaceuticals, Inc.
News Provided by Acquire Media